Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced the commencement of the marketing of its primary product, ColoAlert®, in Switzerland. This development marks a significant milestone following several key achievements by the company. Earlier this year, Mainz Biomed entered into a strategic partnership with labor team w ag, a leading diagnostics laboratory in Switzerland, to ensure the nationwide distribution of ColoAlert through an established and trusted network. The test has been officially registered and approved for distribution by Swissmedic, the Swiss agency for therapeutic products, enabling access to innovative colorectal cancer screening solutions for Swiss patients. In addition, a comprehensive technology transfer has been successfully completed, allowing the local processing and evaluation of ColoAlert samples in Goldach, Switzerland. Meanwhile, the company is advancing the recruitment for its feasibility study, which aims to include around 2,000 patients with an average risk of colorectal cancer. The results of this study will be presented after the evaluation of the entire dataset is completed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2202480_de), on September 23, 2025, and is solely responsible for the information contained therein.
Comments